imbria Pharmaceuticals
- Biotech or pharma, therapeutic R&D
Imbria is a clinical stage company developing ninerafaxstat for the treatment of a spectrum of cardiovascular diseases. We are initiating a Ph2b study in non-obstructive hypertrophic cardiomyopathy which will read out in 2026. We are funded by a top tier syndicate anchored by RA Capital, SV Health Investors, Deep Track Capital, Catalio Capital Management, AN Venture, and Cytokinetics Inc.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}